The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > 2020 > 7 > Recon: Drugmakers launch $1B antibiotic development fund; Moderna taps Rovi to supply coronavirus va

Recon: Drugmakers launch $1B antibiotic development fund; Moderna taps Rovi to supply coronavirus vaccine outside US

Posted 09 July 2020 | By Michael Mezher 

Recon: Drugmakers launch $1B antibiotic development fund; Moderna taps Rovi to supply coronavirus vaccine outside US

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
In Focus: US
  • In race to bring vaccine to market, big pharma struggles to protect its intellectual property rights (CNBC)
  • Who Gets a Vaccine First? US Considers Race in Coronavirus Plans (NYTimes)
  • Grave Shortages of Protective Gear Flare Again as Covid Cases Surge (NYTimes)
  • Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light (Fierce) (Press)
  • Drug Derived From Plasma of Covid-19 Patients to Be Tested as Preventive Measure (WSJ)
  • Merck expands Zymeworks antibody alliance, adding close to $900M in milestones (Endpoints)
  • The home run count: The $100M+ mega-round boom in biotech inspired a $7.3B feeding frenzy — so far this year (Endpoints)
In Focus: International
  • Pharma industry commits $1bn to fight drug-resistant superbugs (Financial Times) (Washington Post) (Press)
  • Moderna in Pact With Rovi to Supply Virus Vaccine Outside US (Bloomberg)
  • Independent evaluation of global COVID-19 response announced (WHO)
  • Gilead to deliver more remdesivir to Europe from autumn: WiWo (Reuters)
  • Sanofi pays $150M upfront, $2B in biobucks to tap protein degrader biotech Kymera (Fierce) (Endpoints)
  • Indian Company Starts Mass-Producing Coronavirus Vaccines Before Trials (NPR)
Coronavirus Pandemic
  • Study of 17 Million Identifies Crucial Risk Factors for Coronavirus Deaths (NYTimes)
  • A flawed Covid-19 study gets the White House’s attention — and the FDA may pay the price (STAT)
  • The first round of Covid-19 vaccines is ‘highly unlikely to be a magic bullet,’ Medicago CEO says (STAT)
  • States with severe coronavirus outbreaks should ‘seriously look at shutting down,’ Dr. Fauci says (CNBC)
  • ‘People can’t ignore it anymore’: Across the country, minorities hit hardest by pandemic (Politico)
  • Oxford researchers develop portable COVID-19 test costing less than $25 (Fierce)
  • Providers, insurers back ad campaign urging patients to stop 'medical distancing' (BioPharmaDive)
  • Coronavirus (COVID-19) Update: Daily Roundup July 8, 2020 (FDA)
Pharma & Biotech
  • Shingles Vaccination Rate Soars But Leaves Many Behind (KHN)
  • A new study points to $6.5B in public support building foundation of remdesivir. Should that be reflected in the price? (Endpoints)
  • After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought (Endpoints)
  • Baloxavir for Postexposure Prophylaxis against Influenza in Households (NEJM)
  • Mylan and Pfizer roll out tricolor branding for their giant generics combo, Viatris (Fierce)
  • Drug Companies Reserving Seat for Patent Lawyers at Deal Table (Bloomberg)
  • Another biotech IPO set-up? Multinational biotech leaps from round to round, scooping up cash at a blistering pace (Endpoints)
  • Forbion spotlights late-stage plays, carves out new €250M growth fund (Endpoints)
  • Stanford star oncology scientist Ed Engleman helped create the immunotherapy field. Now he wants to shake up neurodegeneration R&D (Endpoints)
  • The Cost Of ‘Stacking’ Orphan Indications And A Case For Reform (Pink Sheet)
  • Urgent action required to revive the Indian pharma ancillary industry: IPA (Economic Times)
  • LEO Pharma announces U.S. Food and Drug Administration (FDA) acceptance of Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (Press)
  • Technology Bridges the Gap to Better Sight (NYTimes)
  • Newest Medtronic implantable heart monitor gets FDA nod as remote device features proliferate (MedtechDive)
  • Intersect ENT stock jumps on report of potential Medtronic takeover (MedtechDive)
  • Philips wins $100M tele-ICU contract from VA (MedtechDive)
  • Q2 previews show coronavirus diagnostics bump for Thermo Fisher, Quidel, GenMark (MedtechDive)
  • FDA clears Nonin's hand-held carbon monoxide poisoning meter for first responders (Fierce)
  • Baxter Announces U.S. FDA Clearance of Altapore Shape Bioactive Bone Graft for Use in Surgery (Press)
  • FDA clears Therapixel’s Mammoscreen (MassDevice)
  • Medtronic, Tandem Diabetes Care bury the hatchet on potential IP disputes (MassDevice)
Government & Regulatory
  • Pompeo: State Department 'will work with Congress' on pledged funding to WHO (The Hill)
  • One Federal Agency Was Suing Him for Fraud. Another Paid His Company Millions for Masks. (ProPublica)
  • AbbVie may face fewer wrinkles after judge suggests a 10-year ban on a Botox rival (STAT)
  • ALJ Recommends Exclusion in Botox Trade Secret Case (Big Molecule Watch)
  • Ohio Ruling Adds To Insurance Uncertainty For Opioid Suits (Law360)
  • Wholesaler Dropped As Lead In ADHD Drug Antitrust Suit (Law360)
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
A story's inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.


© 2021 Regulatory Affairs Professionals Society.

Tags: US, worldwide

Regulatory Focus newsletters

All the biggest regulatory news and happenings.